Colorectal adenocarcinoma

This early-phase study tests a new vaccine called YMN-136 in 9 people with advanced colorectal cancer that has spread to the liver and has not responded to three prior treatments. The main goals are to check the vaccine's safety and find the best dose. Researchers will also watch…

This phase 2 trial tests whether two immunotherapy drugs, botensilimab and balstilimab, can clear tiny amounts of cancer DNA from the blood of people with stage II or III colorectal cancer who have completed standard treatment. The study enrolls 20 adults whose blood still shows …

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This early-phase trial is testing whether adding an experimental drug called ZEN003694 to two approved cancer drugs (cetuximab and encorafenib) can help patients with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study involves 30 a…

This early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This study tests an experimental pill called VS-7375, designed to block a specific cancer-driving protein (KRAS G12D). The trial includes people with metastatic colorectal cancer that has this mutation. Some participants receive VS-7375 alone, others get it combined with an antib…

This phase 2 trial is testing whether adding two extra drugs—bevacizumab and sintilimab—to the usual combination of irinotecan and cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to irinotecan. The study enrolls 160 adults with RAS wi…

Researchers are testing a new drug, VVD-133214, combined with pembrolizumab in people with advanced colorectal cancer that has MSI and/or dMMR. These tumors rely on a protein called Werner helicase to survive, and VVD-133214 is designed to block it. The trial compares the combina…

This early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…

Researchers are testing whether a combination of two drugs, atezolizumab and bevacizumab, can clear tiny amounts of cancer DNA from the blood of people whose gastrointestinal cancer was treated with curative intent. The trial enrolls 20 adults with colon, rectal, gastric, pancrea…

This phase 3 trial is testing whether adding the targeted drugs calderasib and cetuximab to standard chemotherapy can help people with a specific gene mutation (KRAS G12C) in advanced colorectal cancer live longer without their cancer growing. About 477 participants will receive …

This study tests whether a new drug called pumitamig, combined with chemotherapy, works better than the current standard treatment (bevacizumab plus chemo) for people with advanced colorectal cancer that cannot be removed by surgery. About 990 adults who have not yet been treated…

This phase 3 trial tests whether adding the experimental drug SHR-A1811 to standard chemotherapy and bevacizumab works better than standard therapy alone for people with advanced colorectal cancer who have not had prior treatment. About 300 participants will receive either the ne…

This phase 3 trial tests whether a new drug called petosemtamab, combined with chemotherapy, works better than the current standard treatment (cetuximab plus chemotherapy) for people with left-sided colorectal cancer that cannot be surgically removed or has spread. The study incl…

This early-phase trial is testing whether adding an experimental drug called CA-4948 to standard chemotherapy (FOLFOX) and a targeted therapy (bevacizumab) is safe for people with metastatic colorectal cancer. About 24 adults whose cancer has spread and cannot be surgically remov…

This trial is testing whether combining pidnarulex (a drug that blocks cancer cell growth) with cemiplimab (an immunotherapy that helps the immune system attack cancer) is safe and effective for people with advanced colorectal cancer that no longer responds to standard treatments…

This early-stage trial tests a new drug called INBRX-109 in people with advanced solid tumors, including Ewing sarcoma and colorectal cancer. The drug is designed to attach to a protein on cancer cells and trigger their death. The main goals are to check safety and see if the dru…

This Phase 3 study tests whether adding the targeted drug sotorasib and another drug called panitumumab to standard chemotherapy (FOLFIRI) works better than standard chemo alone (with or without bevacizumab) for people with metastatic colorectal cancer that has a specific KRAS G1…

This phase III trial is testing whether adding focused treatments—like high-dose radiation, surgery, or heat ablation—to standard chemotherapy can help people with colorectal cancer that has spread to up to four sites. The goal is to see if destroying those metastatic tumors impr…

This study tests if immunotherapy drugs (cemiplimab, fianlimab, and REGN7075) can clear leftover cancer DNA in the blood of colorectal cancer patients after surgery and chemotherapy. The goal is to delay or prevent the cancer from coming back. About 79 adults with stage II/III co…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This phase 2 trial tests whether combining two drugs—fruquintinib and TAS-102—works better than fruquintinib alone for people with advanced colorectal cancer that hasn't responded to prior treatments. About 120 adults will be randomly assigned to one of the two groups. The main g…

This phase II trial tests whether adding paclitaxel directly into the abdomen, alongside standard systemic chemotherapy, is feasible for people with gastrointestinal cancers that have spread to the peritoneal lining. The study includes patients with gastric, colorectal, appendice…

This early-phase study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and to check for side effects. About …

This early-stage trial tests a drug called ACM-CpG, which is injected directly into the abdomen to stimulate the immune system against cancer. It includes 24 adults with colorectal or appendix cancer that has spread to the lining of the abdomen or caused fluid buildup. The main g…

This early-stage trial is testing a new treatment called DISP-10 for people with advanced gastrointestinal cancers, including colorectal and stomach cancers. The treatment combines a virus (DV-10) with specially engineered immune cells (CAR T cells) to attack cancer. The study ai…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This study tests a new drug called AMT-676 combined with standard chemotherapy and targeted therapy for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors or slow the disease. About 180 a…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…

This phase 2 trial is testing whether combining yttrium-90 radioembolization (a procedure that delivers radiation directly to liver tumors) with two drugs—capecitabine (chemotherapy) and atezolizumab (immunotherapy)—can control or shrink liver metastases in people with colorectal…

This phase 1 trial is testing whether fluoxetine (Prozac), a common antidepressant, can change the immune cells inside colorectal tumors. Ten patients with untreated colorectal cancer will take fluoxetine before surgery. Researchers will compare tumor samples taken before and aft…

This phase 2 trial is testing a new immunotherapy drug called volrustomig, combined with standard chemotherapy (FOLFIRI) and bevacizumab, in 120 people with metastatic colorectal cancer. The goal is to see if the combination is safe and helps control the cancer longer. Participan…

This phase 2 trial is testing whether combining three drugs—fruquintinib, pirfenidone, and pembrolizumab—can help people with advanced or metastatic colorectal cancer that has not responded to standard treatments. The study includes 25 participants with a specific type of tumor (…

This Phase 3 trial is testing whether a new medicine called PF-08634404, combined with standard chemotherapy, works better than the current treatment Avastin plus chemo for people whose colorectal cancer has spread. About 800 participants who have not had prior treatment for meta…

This trial tests whether delivering chemotherapy directly to the liver through a pump, combined with standard systemic chemotherapy, can shrink liver tumors from colorectal cancer enough to allow surgery. The study enrolls people whose liver metastases are initially inoperable bu…

This phase 3 trial is testing whether an experimental immunotherapy called IBI363, combined with the anti-angiogenic drug bevacizumab, can help people with advanced colorectal cancer that has stopped responding to standard treatments. About 550 adults whose cancer has progressed …

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This study tests an experimental drug called GSK5764227, given alone or with other treatments, in 320 people with advanced gastrointestinal cancers that have not responded to prior therapy. The main goal is to see if the drug can shrink tumors and how safe it is. It is an early-s…

This early-phase trial tests a combination of two drugs—temozolomide and M1774—in people with advanced solid tumors that have spread. Temozolomide damages cancer cell DNA, while M1774 blocks enzymes that help cancer grow. The goal is to find the best dose and see if the combo can…

This study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if these combinations are safe and can shrink tumo…

This Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrin…

This phase II trial is testing whether combining two targeted drugs—fruquintinib, which blocks blood vessel growth to tumors, and cetuximab-beta, which blocks a cancer growth signal—can shrink tumors in people with RAS wild-type metastatic colorectal cancer who have already tried…

This early-stage study is testing a new oral drug, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Abo…

This phase II trial is testing whether adding the immunotherapy drug adebrelimab and the cholesterol-lowering drug simvastatin to standard chemotherapy and targeted therapy can shrink tumors in people with advanced colorectal cancer that has not responded to prior treatment. The …

This early-stage trial is testing an experimental drug called CHS-114 combined with the immunotherapy toripalimab, with or without standard chemotherapy, in 154 people with advanced or metastatic solid tumors. The main goal is to see if the combination is safe and to get an early…

This phase 4 trial is testing the safety and effectiveness of the oral drug fruquintinib in 78 adults from minority groups (Black/African American and Hispanic/Latino) with advanced colorectal cancer that hasn't responded to other treatments. The main focus is on how often high b…

This early-stage trial tests a new drug, BAY 3771249, that targets a specific cancer-driving mutation called KRAS G12D. It is for people with advanced or metastatic colorectal cancer who have this mutation and have tried other treatments. The drug is given alone or with another c…

This phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…

This study tests whether giving two immunotherapy drugs (botensilimab and balstilimab) before surgery can shrink tumors and improve outcomes for people with advanced colon cancer that can be removed. About 100 adults with stage IIB to IIIC colorectal cancer will receive the drugs…

This study tests a new drug called arfolitixorin for people with metastatic colorectal cancer (cancer that has spread). The drug is a form of vitamin B that may make standard chemotherapy work better. About 90 participants will receive arfolitixorin along with usual chemo drugs, …

This study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…

This Phase 3 trial tests whether adjusting the dose of bevacizumab based on each patient's drug levels can better control metastatic colorectal cancer. About 244 people will receive either standard or personalized dosing alongside chemotherapy. The main goal is to see if personal…

This phase II trial tests whether a blood test that looks for genetic changes in circulating tumor cells can help doctors choose the right targeted therapy for colorectal cancer. 150 participants will either get treatment guided by the blood test or standard care. The goal is to …

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This study tests whether giving additional chemotherapy to people with stage III colorectal cancer who still have cancer DNA in their blood after standard treatment can prevent the cancer from coming back. About 1,660 participants will be randomly assigned to receive either FOLFI…

This study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…

This study is testing whether a simple blood test that measures tumor DNA (ctDNA) can help doctors decide how much chemotherapy to give before surgery for colorectal or appendix cancer that has spread to the abdomen. The goal is to see if the test can identify patients who need s…

This early-stage trial tests a new type of immune cell therapy (CAR-NK cells) in people with advanced colorectal cancer that has not responded to standard treatments. The cells are designed to target two cancer-related proteins at once, based on each patient's tumor markers. The …

This study tests different combinations of immunotherapy drugs (with or without radiation) in 24 people with colorectal cancer that has spread to the liver and who are scheduled for surgery. The goal is to see if these treatments change the immune environment inside the liver tum…

This phase 2 trial tests two drugs, fulzerasib and cetuximab N01, given before surgery to people with a specific genetic subtype (KRAS G12C mutation) of locally advanced colorectal cancer. The goal is to shrink tumors and improve surgical outcomes without using chemotherapy. Fort…

This early-phase trial tests a two-step vaccine strategy in adults with advanced colorectal or small bowel cancer that has stopped responding to standard treatments. Participants first receive one vaccine injection, followed by two doses of a second vaccine four weeks apart. The …

This study looks at whether drinking instant coffee every day for 6 weeks can reduce liver fat and improve gut health in people who have finished treatment for stage I-III colorectal cancer. About 80 adults who completed surgery, chemo, or radiation at least 2 months ago will par…

This study tests a new drug called JS212, which is designed to target two proteins on cancer cells (EGFR and HER3) and deliver a chemotherapy-like payload directly to them. It is being tested in combination with other standard cancer drugs in 80 adults with metastatic colorectal …

This early-phase study tests a combination of two drugs—trifluridine/tipiracil (a chemotherapy) and talazoparib (a targeted therapy)—in people with advanced colorectal or gastroesophageal cancers that have spread. The main goals are to find the safest dose and understand side eff…

This study tests whether adding radiotherapy to a drug combination (fruquintinib and sintilimab) can help control colorectal cancer that has spread to the liver and hasn't responded to two prior treatments. About 62 adults with a specific type of colorectal cancer (MSS/pMMR) will…

This early-phase study tests an experimental drug called KQB365 in adults with advanced solid tumors that have KRAS G12S or G12C mutations and haven't responded to standard treatments. The main goals are to find a safe dose and see if KQB365 alone or combined with other drugs can…

This study tests a new nanovaccine made from engineered bacteria that targets KRAS mutations in colorectal and pancreatic cancer patients who have had surgery and chemotherapy but are at high risk of their cancer coming back. The vaccine is designed to train the immune system to …

This study tests whether a combination of three drugs (tucidinostat, sintilimab, and bevacizumab) can help people with a specific type of advanced colorectal cancer (MSS/pMMR) who have already tried at least two standard treatments. About 430 adults aged 18 to 75 will be randomly…

This early-phase trial is testing whether combining two immunotherapy drugs (botensilimab and balstilimab) with a low-sugar, calorie-restricted diet and high-dose vitamin C is safe and tolerable for people with a specific type of advanced colorectal cancer (KRAS-mutant). The stud…

This study tests a new drug, tegavivint, in people with metastatic colorectal cancer that has worsened after at least two prior treatments. The trial aims to find a safe dose and see if the drug shrinks tumors when used alone or with standard therapies. About 126 adults with spec…

This study tests a new treatment made from donated cord blood cells that are engineered to recognize and attack colorectal cancer cells. It is for people with advanced or metastatic colorectal cancer that has not responded to standard treatments. The trial will check safety and e…

This study tests whether a single, extremely high dose of radiation, guided by advanced MRI technology, can control liver tumors that have spread from other cancers better than the usual high dose. About 114 adults with up to 3 liver metastases will be randomly assigned to receiv…

This phase 3 study compares a new drug, AK112, combined with chemotherapy against the standard treatment (bevacizumab plus chemo) for people with metastatic colorectal cancer that has not been treated before. The goal is to see if the new combination helps patients live longer wi…

This study tests a combination of three drugs (trastuzumab-deruxtecan, capecitabine, and bevacizumab) as a first treatment for people with HER-2 positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see how well the drugs shrink tumors. About …

This early-phase trial is testing a new drug called CLSP-1025 in about 90 adults with advanced solid tumors (like lung, colon, or breast cancer) that have a specific p53 mutation (R175H). The drug works by directing the body's immune cells to attack cancer cells carrying this mut…

This Phase II trial tests a combination of two drugs, anlotinib and sintilimab, as a first treatment for advanced colorectal cancer that has spread but not to the liver. The goal is to shrink tumors and control the disease without using standard chemotherapy. About 37 patients wh…

This study tests a pump that delivers chemotherapy directly to the liver for people with colorectal cancer or bile duct cancer that has spread to the liver. The goal is to see if the pump is safe and if patients can get their pump refilled at a local clinic instead of always trav…

This phase 3 trial tests the immunotherapy drug dostarlimab against standard chemotherapy in 892 people with a specific type of colon cancer (dMMR/MSI-H) that has not spread. The goal is to see if dostarlimab alone can prevent cancer from coming back or causing death. Participant…

This study tests whether combining the targeted drug cabozantinib with immunotherapy drugs (durvalumab, with or without tremelimumab) is safe and effective for people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that c…

This study tests a new medicine, GSK5764227, that delivers a toxin directly to cancer cells to destroy them while leaving healthy cells alone. It is given together with standard treatments to people with advanced solid tumors like colorectal or prostate cancer. The main goals are…

This Phase 3 trial tests whether a new combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than the standard FOLFOX regimen for people with metastatic colorectal cancer that has not been treated before. About 144 participants will receive one of the t…

This study tests whether adding two drugs (bevacizumab and a PD-1 inhibitor) to standard chemotherapy before surgery can improve outcomes for people with a common, hard-to-treat type of colorectal cancer. About 166 adults with locally advanced pMMR/MSS colorectal cancer will be r…

This phase 2 trial tests a combination of two drugs—futibatinib (a daily pill) and tislelizumab (an IV immunotherapy)—in adults with advanced colorectal cancer. The goal is to see if the combo can shrink tumors and to identify biomarkers that predict response. About 33 people wil…

This study tests a new form of chemotherapy (liposomal irinotecan) combined with standard drugs for people with advanced colorectal cancer that has not responded to first treatment. About 100 adults aged 18-75 will receive this combination to see if it shrinks tumors and delays c…

This early-stage study tests whether combining two drugs (sacituzumab govitecan and capecitabine) is safe for people with advanced gastrointestinal cancers that have stopped responding to standard treatments. About 20 adults with stomach, colorectal, or pancreatic cancer will tak…

This phase 2 trial tests whether adding an immunotherapy drug (envafolimab) and a stronger chemotherapy mix (mFOLFOXIRI) to the standard treatment (cetuximab plus mFOLFOX6) can better control advanced left-sided colorectal cancer that has spread. About 198 people with a specific …

This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…

This study tests whether taking a postbiotic supplement (butyrate) for 7 days before colorectal cancer surgery can lower the chance of complications like infections or bowel issues. Researchers will compare complication rates in 164 adults who get the supplement versus those who …

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participants with various cancers, including lung, mel…

This study tests whether a combination of targeted drugs (cetuximab beta and fruquintinib) with or without immunotherapy can control advanced colorectal cancer without traditional chemotherapy. About 70 people with a specific genetic type (RAS/BRAF wild-type) will receive these d…

This phase 2 trial is testing whether adding an immunotherapy drug (AK104) to standard chemotherapy and a targeted therapy (cetuximab or bevacizumab) can shrink tumors in people with a specific type of advanced colorectal cancer (MSS type) that has already been treated once. The …

This phase 2 trial tests whether adding an immune checkpoint inhibitor (a type of immunotherapy) to standard chemotherapy before surgery can improve outcomes for people with locally advanced colorectal cancer. About 170 participants will be randomly assigned to receive either the…

This study tests whether the antibiotic metronidazole can lower the amount of a specific bacteria (Fusobacterium nucleatum) in colorectal cancer tumors. About 40 adults with untreated colorectal cancer will take metronidazole before surgery. Researchers will compare bacteria leve…

This study tests whether adding a non-invasive device that delivers low-level radio waves (AM RF EMF) to the targeted drug fruquintinib can help people with metastatic colorectal cancer that has stopped responding to other treatments live longer. About 102 participants will recei…

This phase 2 trial is testing whether a combination of two drugs, pembrolizumab and odetiglucan, can safely shrink tumors in people with colorectal cancer that has spread mainly to the liver. About 27 participants will receive the drugs every three weeks. The main goal is to see …

This study tests A2B395, a donor-derived CAR T-cell therapy designed to target cancer cells while sparing healthy ones. It is for adults with advanced solid tumors like colorectal, lung, or breast cancer that have lost a specific immune marker. The trial has two phases: first to …

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This study is testing a new blood test called DENEB that looks for tiny molecules (microRNAs) to find colorectal cancer and precancerous polyps early. Researchers will collect blood samples from 2,000 people who are also getting a colonoscopy. The goal is to see if the blood test…

This study is developing a blood test that uses tiny particles called exosomes and machine learning to detect colorectal cancer in people under 50. The test looks for specific microRNA patterns in the blood. Researchers will compare results from 400 people—some with cancer and so…

This study aims to develop a blood test that uses epigenetic markers (chemical changes on DNA) to predict whether a patient with metastatic colorectal cancer will respond to targeted therapies like cetuximab or bevacizumab. Researchers will analyze blood samples from 500 patients…

This trial is testing whether doing a colonoscopy 5 to 8 days after low colorectal cancer surgery can help doctors spot anastomotic leaks earlier than standard monitoring. About 140 adults who had surgery for colorectal cancer will either get an early colonoscopy or routine care.…

Colon cancer is common but preventable if caught early. While colonoscopy is the best screening tool, many people can't get one due to cost or time. This study collects stool and blood samples from 1,200 adults to find proteins that signal colon polyps or cancer. The goal is to d…

This study is testing whether a blood test that measures a protein called MMP14 can help screen for colorectal cancer. Researchers will enroll 650 people aged 50 to 74 who already need a colonoscopy after a positive stool test. By comparing MMP14 levels with colonoscopy results, …

This study tests a special dye and imaging system to help surgeons see colorectal, pancreatic, esophageal, and stomach cancers during surgery. About 66 adults scheduled for cancer surgery will receive the dye, and the imaging system will check if it lights up cancer tissue. The g…

This study tests a new microwave-based device, called MiWEndo, that is used during a standard colonoscopy to help doctors find polyps in the colon. About 50 people who already have a polyp in their rectum will take part. The goal is to see if the device is safe and can find more …

This study is testing whether eating a high-fiber, low-fat diet for three weeks before colorectal cancer surgery can change gut bacteria to help prevent the cancer from returning or spreading. About 80 adults with colorectal cancer will follow this diet and provide blood, stool, …

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests a daily injection called TCMCB07 in 120 people with newly diagnosed colorectal cancer who are starting chemotherapy. The goal is to see if it can help maintain body weight and muscle mass, which often drop during treatment. Participants will receive either the st…

This study tests a telehealth program called ENGAGE for people with stage IV breast, prostate, lung, or colorectal cancer. The program helps manage symptoms like pain, fatigue, and distress that interfere with daily life. About 190 participants will be randomly assigned to ENGAGE…

Researchers are exploring whether an experimental compound called BPR001-615 can reduce the growth of colorectal cancer cells taken directly from patients during surgery. The study also measures levels of a protein called BiP in blood and tumor tissue to see whether it could serv…

This study looks at whether having a healthcare provider directly contact close relatives of people with newly diagnosed colorectal cancer leads to more genetic testing than having the patient share the information themselves. About 4,186 patients and their relatives will take pa…

This study tests a new method called mass-based response testing (MRT) to help doctors choose the best chemotherapy drugs for patients with advanced appendix or colorectal cancer that has spread to the abdomen. The MRT device analyzes live tumor cells to see which drugs work best…

This study looks at medical records of 51 patients aged 70 and older with metastatic colorectal cancer. Researchers want to see if using lower doses of chemotherapy along with full-dose targeted therapy can reduce serious side effects like low white blood cell counts and severe d…

This study looks at whether monitoring bowel sounds before and after colorectal cancer surgery can help doctors assess how well the intestines are recovering. Researchers will track 172 patients and compare bowel sound patterns with outcomes like time to first gas, ability to eat…

This study aims to develop a test that uses DNA methylation patterns from tumor samples to predict whether stage II or III colorectal cancer will return after surgery and chemotherapy. Researchers will analyze tissue from 400 patients who are currently cancer-free after treatment…

This study is looking for a way to predict which patients with advanced colorectal cancer will benefit from standard chemotherapy. Researchers will analyze blood samples from 600 patients to find specific markers that separate responders from non-responders. The goal is to help d…

This study is testing whether growing a patient's tumor cells in the lab (as 3D 'organoids') can help doctors pick the best drug for advanced cancers that have stopped responding to standard treatments. About 152 adults with colorectal or pancreatic cancer will have a biopsy to c…

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study is testing if a simple blood test can find tiny bits of tumor DNA left after treatment, which might help doctors know if colorectal cancer will return sooner than current methods. About 1,000 people with colorectal cancer who have finished or are about to start treatme…

This study watches 40 adults with colorectal cancer who have no visible tumors but still have cancer DNA in their blood (minimal residual disease). Researchers will see how well biomarker-directed therapy, chosen by their own doctor, works to clear that DNA. The goal is to learn …

This study collects tumor samples from 60 patients with colorectal cancer before they receive any chemotherapy. Researchers will grow mini-tumors (organoids) in the lab to study how the immune system and tumor cells interact. The goal is to understand why 30-50% of patients do no…

This study tests whether artificial intelligence can predict serious complications after colorectal cancer surgery by analyzing CT scans, MRI, and tissue images. Researchers will look back at data from 750 past patients and also study 210 future patients. The goal is to see if AI…

This study looks at how chemotherapy and radiation affect the reproductive and sexual health of young adults with early onset colorectal cancer. Researchers will track hormone levels and fertility over time in 120 men and women. The goal is to better understand the long-term effe…

This study looks at whether a blood test for tumor DNA can better predict if colorectal cancer will come back after surgery. Currently, doctors use tumor tissue to decide who needs chemotherapy, but many patients get chemo they may not need. The test checks for cancer DNA in the …

This study is for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. Researchers want to learn how the body responds to a treatment called SIRT, which delivers tiny radioactive beads to the liver. They will collect blood and tissue sample…